Ocugen to Present at BIO International Convention 2023
23 Maio 2023 - 9:00AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines, today announced that the Company will present at the 2023
BIO International Convention taking place in Boston, Mass. from
June 5-8, 2023.
During the conference, members of the Ocugen team will host
meetings with pharmaceutical executives to explore partnering and
strategic opportunities for the Company’s diverse and robust
clinical pipeline—specifically its ophthalmic modifier gene therapy
platform, including OCU400, and the inhalation vaccines
portfolio.
“Our dynamic clinical development pipeline offers the potential
to address debilitating diseases that remain underserved by current
therapeutic options,” said Dr. Shankar Musunuri, Chairman, Chief
Executive Officer, and Co-Founder of Ocugen. “Our goal at Ocugen is
to maximize the value of our pipeline for patients and
shareholders, including the assessment of potential business
development opportunities. BIO International provides an ideal
venue for such conversations, and we look forward to actively
engaging with the pharma and biotech community in attendance.”
Ocugen’s presentation details are as follows:
Event: BIO 2023 International Convention
Date: Monday, June 5, 2023
Time: 4:30 p.m. EDT
Location: Room 104B, Boston Convention and
Exhibition Center
Presenter: Quan Vu, Chief Financial Officer
& Chief Business Officer
Please visit Ocugen at Booth #675 to learn more about the
Company’s clinical programs and the potential they may hold for
patients.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks, and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany HamiltonHead of
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocugen (NASDAQ:OCGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024